FibroGen (FGEN) Receives FDA Clearance to Proceed with FG-3019 Study in DMD

July 27, 2015 4:19 PM EDT Send to a Friend
FibroGen (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company's investigational ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login